IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY

被引：0

作者：

Trneny, M. ^{[1
]}

Lamy, T. ^{[2
]}

Walewski, J. ^{[3
,4
]}

Belada, D. ^{[5
,6
]}

Mayer, J. ^{[7
]}

Radford, J. ^{[8
,9
]}

Jurczak, W. ^{[10
]}

Morschhauser, F. ^{[11
]}

Alexeeva, J. ^{[12
]}

Rule, S. ^{[13
]}

Biyukov, T. ^{[14
]}

Patturajan, M. ^{[15
]}

Bravo, M. L. Casadebaig ^{[14
]}

Arcaini, L. ^{[16
,17
]}

机构：

[1] Charles Univ Hosp, Dept Hematol, Prague, Czech Republic

[2] Hop Pontchaillou, Dept Hematol, Rennes, France

[3] Maria Sklodowska Curie Mem Inst Oncol, Dept Lymphoid Malignancies, Warsaw, Poland

[4] Ctr Oncol, Warsaw, Poland

[5] Charles Univ Hosp, Dept Internal Med Haematol 4, Hradec Kralove, Czech Republic

[6] Fac Med, Hradec Kralove, Czech Republic

[7] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[8] Univ Manchester, Dept Med Oncol, Manchester, Lancs, England

[9] Christie NHS Fdn Trust, Manchester, Lancs, England

[10] Jagiellonian Univ, Dept Hematol, Krakow, Poland

[11] Ctr Hosp Univ Reg Lille, Lille, France

[12] Fed Med Res Ctr, St Petersburg, Russia

[13] Derriford Hosp, Dept Haematol, Plymouth PL6 8DH, Devon, England

[14] Celgene Int Sarl, Boudry, Switzerland

[15] Celgene Corp, Summit, NJ USA

[16] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy

[17] Univ Pavia, Dept Mol Med, I-27100 Pavia, Italy

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S107

引用

页码：4 / 4

页数：1

共 50 条

[1] Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator's choice in relapsed/refractory mantle cell lymphoma
Trneny, Marek
Lamy, Thierry
Walewski, Jan Andrzej
Belada, David
Mayer, Jiri
Radford, John A.
Jurczak, Wojciech
Morschhauser, Franck
Alexeeva, Julia
Rule, Simon
Biyukov, Tsvetan Nikolov
Patturajan, Meera
Bravo, Marie-Laure Casadebaig
Cabecadas, Jose
Arcaini, Luca
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[2] Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
Arcaini, Luca
Lamy, Thierry
Walewski, Jan
Belada, David
Mayer, Jiri
Radford, John
Jurczak, Wojciech
Morschhauser, Franck
Alexeeva, Julia
Rule, Simon
Cabecadas, Jose
Campo, Elias
Pileri, Stefano A.
Biyukov, Tsvetan
Patturajan, Meera
Casadebaig Bravo, Marie-Laure
Trneny, Marek
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (02) : 224 - 235
[3] Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator's Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study
Trneny, Marek
Lamy, Thierry
Walewski, Jan
Jurczak, Wojciech
Belada, David
Mayer, Jiri
Radford, John
Alexeeva, Julia
Osmanov, Dzhelil
Biyukov, Tsvetan
Patturajan, Meera
Bravo, Marie-Laure Casadebaig
Arcaini, Luca
BLOOD, 2014, 124 (21)
[4] QUALITY OF LIFE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS TREATED WITH LENALIDOMIDE VS INVESTIGATOR'S CHOICE: MCL-002 (SPRINT) TRIAL
Rule, S.
Arcaini, L.
Walewski, J.
Skotnicki, A.
Belada, D.
Mayer, J.
Alexeeva, J.
Afanasyev, B.
Kuzmin, A.
Jurczak, W.
Kaplanov, K.
Voloshin, S.
Radford, J.
Le Gouill, S.
Biyukov, T.
Patturajan, M.
Casadebaig-Bravo, M. L.
Mahmoud, D.
Hu, X. H.
Trneny, M.
HAEMATOLOGICA, 2015, 100 : 147 - 147
[5] Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
Trneny, Marek
Lamy, Thierry
Walewski, Jan
Belada, David
Mayer, Jiri
Radford, John
Jurczak, Wojciech
Morschhauser, Franck
Alexeeva, Julia
Rule, Simon
Afanasyev, Boris
Kaplanov, Kamil
Thyss, Antoine
Kuzmin, Alexej
Voloshin, Sergey
Kuliczkowski, Kazimierz
Giza, Agnieszka
Milpied, Noel
Stelitano, Caterina
Marks, Reinhard
Truemper, Lorenz
Biyukov, Tsvetan
Patturajan, Meera
Bravo, Marie-Laure Casadebaig
Arcaini, Luca
LANCET ONCOLOGY, 2016, 17 (03): : 319 - 331
[6] MCL-002: UPDATED EFFICACY AND SAFETY RESULTS FOR LENALIDOMIDE VSINVESTIGATOR'S CHOICE MONOTHERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Arcaini, L.
Rule, S.
Lamy, T.
Walewski, J.
Belada, D.
Mayer, J.
Radford, J.
Jurczak, W.
Morschhauser, F.
Alexeeva, J.
Biyukov, T.
Patturajan, M.
Bravo, M. L. Casadebaig
Trneny, M.
HAEMATOLOGICA, 2016, 101 : 476 - 476
[7] IMPACT OF STABLE DISEASE OR BETTER RESPONSES TO LENALIDOMIDE ON SURVIVAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: MCL-001 (EMERGE) AND MCL-002 (SPRINT) STUDIES
Goy, A.
Arcaini, L.
Williams, M. E.
Lamy, T.
Besisik, S. K.
Drach, J.
Ramchandren, R.
Witzig, T. E.
Fu, T.
Zhang, L.
Biyukov, T.
Barnett, E.
Bravo, M. L. Casadebaig
Trneny, M.
HAEMATOLOGICA, 2016, 101 : 477 - 477
[8] Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial
Trneny, Marek
Lamy, Thierry
Walewski, Jan
Belada, David
Mayer, Jiri
Radford, John A.
Jurczak, Wojciech
Morschhauser, Franck
Alexeeva, Julia
Rule, Simon A.
Afanasyev, Boris V.
Kaplanov, Kamil
Thyss, Antoine
Kuzmin, Alexej
Voloshin, Sergey
Kuliczkowski, Kazimierz
Giza, Agnieszka
Milpied, Noel
Stelitano, Caterina
Marks, Reinhard
Trumper, Lorenz
Biyukov, Tsvetan
Barnett, Evelyn
Bravo, Marie-Laure Casadebaig
Arcaini, Luca
BLOOD, 2016, 128 (22)
[9] PHASE 3 STUDY OF PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA: COMPARISON OF TREATMENT WITH TEMSIROLIMUS vs INVESTIGATOR'S CHOICE THERAPY
Verhoef, E. G.
He, G.
Romaguera, J.
Herbrecht, R.
Crump, M.
Strahs, A.
Hanushevsky, O.
Binlich, F.
Hewes, B.
Coiffier, B.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 174 - 174
[10] Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study
Williams, Michael E.
Goy, Andre
Sinha, Rajni
Besisik, Sevgi Kalayoglu
Drach, Johannes W.
Ramchandren, Rod
Zhang, Lei
Cicero, Sherri
Fu, Tommy
Witzig, Thomas E.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →